Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Next Previous
X
Search
Trial Profile

A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 25 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Fluoropyrimidine derivatives (Primary) ; GRANITE 001 (Primary) ; Ipilimumab (Primary) ; Oxaliplatin (Primary)
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms GRANITE-CRC-1L
  • Sponsors Gritstone bio

    • Most Recent Events

    • 24 Jul 2024 According to a Gritstone bio media release, mature progression-free survival data from a randomized Phase 2 study of GRANITE in frontline MSS-CRC are expected in the third quarter of 2024.
    • 01 Apr 2024 According to a Gritstone bio media release, company is expecting mature PFS data in the third quarter of 2024 and then enter regulatory discussions regarding Phase 3. overall survival data expected in 1H 2025
    • 01 Apr 2024 Results (from Phase 2 Portion) presented in the Gritstone bio Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top